These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37777180)

  • 1. Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis.
    Nagendra L; Mahajan K; Gupta G; Dutta D
    Indian Heart J; 2023; 75(6):416-422. PubMed ID: 37777180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis.
    Mahajan K; Nagendra L; Dhall A; Dutta D
    Eur J Intern Med; 2024 Jun; 124():99-107. PubMed ID: 38336550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Initiation of PCSK9 Inhibitor Therapy Versus Placebo in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
    Justino GB; Justino LB; Müller ME; Rocha AV; Mazetto A; Cardoso R; Leucker TM
    Am J Cardiol; 2024 Feb; 213():110-118. PubMed ID: 37875235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27 979 Patients With Incident Acute Coronary Syndrome.
    Sarak B; Savu A; Kaul P; McAlister FA; Welsh RC; Yan AT; Goodman SG
    Circ Cardiovasc Qual Outcomes; 2021 Apr; 14(4):e006646. PubMed ID: 33813856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?
    Canonico ME; Hess CN; Cannon CP
    Curr Atheroscler Rep; 2023 Jul; 25(7):381-389. PubMed ID: 37223853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome.
    Hao Y; Yang YL; Wang YC; Li J
    Int Heart J; 2022 Jul; 63(4):669-677. PubMed ID: 35831153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysis.
    Moustafa B; Oparowski D; Testai S; Guman I; Trifan G
    J Stroke Cerebrovasc Dis; 2024 Apr; 33(4):107633. PubMed ID: 38336118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors After Acute Coronary Syndrome: A Meta-analysis of Randomized Controlled Trials.
    Atia A; Aboeldahab H; Wageeh A; Elneny M; Elmallahy M; Elawfi B; Aboelkhier MM; Elrosasy A; Abdelwahab MM; Sayed S; Abdelaziz A
    Am J Cardiovasc Drugs; 2024 Jan; 24(1):83-102. PubMed ID: 38241002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.
    Altunkeser BB; Tuncez A; Ozturk B; Tezcan H; Ates MS; Yilmaz C; Yalcin MU; Aygul N; Demir K
    Coron Artery Dis; 2019 Jun; 30(4):285-290. PubMed ID: 30741744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.
    Lou B; Liu H; Luo Y; Jiang GT; Wu H; Wang C; Wu Y; Zhou B; Yuan Z; She J; Liu J
    Lipids Health Dis; 2022 Oct; 21(1):105. PubMed ID: 36280861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
    Schwartz GG; Giugliano RP
    Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.
    Li C; Lin L; Zhang W; Zhou L; Wang H; Luo X; Luo H; Cai Y; Zeng C
    J Am Heart Assoc; 2015 Jun; 4(6):e001937. PubMed ID: 26077586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of early in-hospital use of PCSK9 inhibitors on cardiovascular outcomes in acute coronary syndrome patients: A systematic review and meta-analysis.
    Yifan D; Yue M; Yubin Z; Jiapei G; Xun S; Shenghu H; Li Z; Jing Z
    Int J Cardiol; 2024 Mar; 399():131775. PubMed ID: 38211676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study).
    Schettler VJ; Muellendorff F; Schettler E; Platzer C; Norkauer S; Julius U; Neumann CL
    Ther Apher Dial; 2019 Oct; 23(5):467-473. PubMed ID: 30663261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice.
    Sabouret P; Puymirat E; Kownator S; Abdennbi K; Lebeau F; Meltz M; Angoulvant D; Schiele F
    Panminerva Med; 2023 Jun; 65(2):244-249. PubMed ID: 36222543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials.
    Benhuri B; Ueyama H; Takagi H; Briasoulis A; Kuno T
    Curr Vasc Pharmacol; 2021; 19(4):390-397. PubMed ID: 32767943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-hospital initiation of a PCSK9 inhibitor in patients with acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials.
    Shi W; Xu Y; Zhou L; Wang W; Huang W; Zhou B
    Medicine (Baltimore); 2024 Mar; 103(10):e37416. PubMed ID: 38457555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.